Advertisement
Original Study| Volume 31, ISSUE 5, P522-525, October 2018

Download started.

Ok

More than Grapes and Bleeding: An Updated Look at Pelvic Rhabdomyosarcoma in Young Women

Published:February 05, 2018DOI:https://doi.org/10.1016/j.jpag.2018.01.006

      Abstract

      Study Objective

      To review our local experience with urogenital rhabdomyosarcoma (RMS) to determine the most common clinical presentation(s).

      Design

      Retrospective case series of all female patients with urogenital RMS who presented to a tertiary pediatric hospital between 1996 and 2016. All institutional electronic pathology reports were screened for RMS and those that were pelvic in origin and occurred in female patients were included for further analysis. Seventeen cases of urogenital RMS in female patients were identified and reviewed.

      Setting

      This study was conducted at The Royal Children's Hospital in Melbourne, Australia. This is a tertiary referral center for the state of Victoria and surrounding areas, which services more than 1.5 million pediatric patients.

      Participants

      Female pediatric patients (ages 0-18 years) who presented to The Royal Children's Hospital with eventual pathologic tissue diagnosis of urogenital RMS.

      Main Outcome Measures

      The cases were reviewed for clinical presentation, duration of symptoms before initial presentation, time to tissue diagnosis, and outcomes of treatment.

      Results

      Of the 17 cases reviewed, 5 (29%) presented with perineal mass, 4 (24%) presented with each of abdominal mass and grape-like lesions/hemorrhagic mass at the introitus, 3 (18%) with nonspecific symptoms only, and 1 (6%) with vulvar inflammation.

      Conclusion

      The clinical presentation of urogenital RMS in women is heterogeneous, and the classically described presentation of grape-like lesions at the introitus and vaginal bleeding represents only a small proportion of clinical presentations. Awareness of other presentations, which appear to be more common than previously recognized, needs to be increased to ensure timely diagnosis and treatment.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Pediatric and Adolescent Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Meyer W.H.
        • Spunt S.L.
        Soft tissue sarcomas of childhood.
        Cancer Treat Rev. 2004; 30: 269
        • Hosoi H.
        Current status of treatment for pediatric rhabdomyosarcoma in the USA and Japan.
        Pediatr Int. 2016; 58: 81
        • Maurer H.M.
        • Beltangady M.
        • Gehan E.A.
        • et al.
        The Intergroup Rhabdomyosarcoma Study-I. A final report.
        Cancer. 1988; 61: 209
        • Maurer H.M.
        • Gehan E.A.
        • Beltangady M.
        • et al.
        The Intergroup Rhabdomyosarcoma Study-II.
        Cancer. 1993; 71: 1904
        • Crist W.
        • Gehan E.A.
        • Ragab A.H.
        • et al.
        The Third Intergroup Rhabdomyosarcoma Study.
        J Clin Oncol. 1995; 13: 610
        • Arndt C.A.
        • Crist W.M.
        Common musculoskeletal tumors of childhood and adolescence.
        N Engl J Med. 1999; 341: 342
        • Paulino A.C.
        • Mehmet F.O.
        Rhabdomyosarcoma.
        Curr Probl Cancer. 2008; 32: 7
        • Copeland L.J.
        Malignant gynecologic tumors.
        in: Sutow W.W. Fernbach D.J. Vietti T.J. Clinical Pediatric Oncology. 3rd ed. CV Mosby Co, St Louis1984 (p. 744-760.)
      1. Pediatric Surgery.
        in: Brunicardi F. Andersen D.K. Billiar T.R. Schwartz's Principles of Surgery. 10th ed. McGraw-Hill, New York, NY2015 (chapter 39, p. 75-76)
      2. Vaginal Cancer.
        in: Hoffman B.L. Schorge J.O. Bradshaw K.D. Williams Gynecology. 3rd ed. McGraw-Hill, New York, NY2016 (chapter 32, p. 7-8)
        • Hilgers R.D.
        • Malkasian Jr., G.D.
        • Soule E.H.
        Embryonal rhabdomyosarcoma (botryoid type) of the vagina: a clinicopathologic review.
        Am J Obstet Gynecol. 1970; 107: 484
        • Copeland L.J.
        • Gershenson D.M.
        • Saul P.B.
        • et al.
        Sarcoma botryoides of the female genital tract.
        Obstetr Genecol. 1985; 66: 262
      3. Australian Bureau of Statistics: 2016 Census QuickStats.
        (Available at:)
        • Stevens M.
        • Rey A.
        • Bouvet N.
        • et al.
        SIOP MMT95: intensified (6 drug) versus standard (IVA) chemotherapy for high risk nonmetastatic rhabdomyosarcoma (RMS).
        J Clin Oncol. 2004; 22: 802s
        • Malempati S.
        • Hawkins D.S.
        Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) Soft Tissue Sarcoma Committee Experience and rationale for current COG studies.
        Pediatr Blood Cancer. 2012; 59: 5
        • Ries L.A.
        • Smith M.A.
        • Gurney J.G.
        • et al.
        Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995.
        National Cancer Institute, SEER Program, Bethesda, MD1999 (Publication #NIH 99-4649)
        • Marcus K.C.
        • Grier H.E.
        • Shamberger R.C.
        • et al.
        Childhood soft tissue sarcoma: a 20-years experience.
        J Pediatr. 1997; 131: 603